Fargo

Futó vizsgálatok

• Toboroz

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

  NCT07619118· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  NCT07776509· 3. fázis· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· 3. fázis· Forrás

• Toboroz

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• 1-es típusú cukorbetegség2 toboroz
• 2-es típusú cukorbetegség2 toboroz
• Elhízás2 toboroz
• Szívelégtelenség2 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

  NCT06862791· 2. fázis· Forrás

• Lezárult

  Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

  NCT06579092· 2. fázis· Forrás

• Lezárult

  Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

  NCT06579105· 2. fázis· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Forrás

• Lezárult

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· 3. fázis· Forrás

• Lezárult

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT05166889· 3. fázis· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· Forrás

• Lezárult

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· Forrás

• Lezárult

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· 2. fázis· Forrás